Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303)

Journal of Clinical Oncology

Volumn 28, Issue 22, 2010, Pages 3617-3622

  Kindler, Hedy Lee ^a   Niedzwiecki, Donna ^a   Hollis, Donna ^a   Sutherland, Susan ^a   Schrag, Deborah ^a   Hurwitz, Herbert ^a   Innocenti, Federico ^a   Mulcahy, Mary Frances ^a   O'Reilly, Eileen ^a   Wozniak, Timothy F ^a   Picus, Joel ^a   Bhargava, Pankaj ^a   Mayer, Robert J ^a   Schilsky, Richard L ^a   Goldberg, Richard M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; GEMCITABINE; PLACEBO; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

ABDOMINAL PERFORATION; ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; EDEMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; LIVER TOXICITY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PERFORATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; VEIN THROMBOSIS; VISCERAL PERFORATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PLACEBOS;

EID: 77955887676     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.1386     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. Burris HA, Moore MJ, Andersen J 3rd, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997 (Pubitemid 27251144)
3. Berlin JD, Catalano P, Thomas JP, et al: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275, 2002 (Pubitemid 34831525)
4. Rocha Lima CM, Green MR, Rotche R, et al: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776-3783, 2004 (Pubitemid 41095218)
5. Van Cutsem E, van de Velde H, Karasek P, et al: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430-1438, 2004 (Pubitemid 41103625)
6. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516, 2005
7. Oettle H, Richards D, Ramanathan RK, et al: A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16:1639-1645, 2005 (Pubitemid 41510138)
8. Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncl 24:3946-3952, 2006 (Pubitemid 46630743)
9. Abou-Alfa GK, Letourneau R, Harker G, et al: Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24:4441-4447, 2006 (Pubitemid 46630982)
10. Herrmann R, Bodoky G, Ruhstaller T, et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Res and the Central European Cooperative Oncology Group. J Clin Oncol 25:2212-2217, 2007 (Pubitemid 46954645)
11. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
12. Ferrara N, Hillan KJ, Gerber HP, et al: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400, 2004 (Pubitemid 38618122)
13. Kindler HL, Friberg G, Singh DA, et al: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23: 8033-8040, 2005 (Pubitemid 46657405)
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
15. Lan KK, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrika 70:659-663, 1983
16. Freidlin B, Korn EL, George SL: Data monitoring committees and interim monitoring guidelines. Control Clin Trials 20:395-407, 1999 (Pubitemid 29460917)
17. Collett D: Modelling Survival Data in Medical Research (ed 2). London, United Kingdom, Chapman & Hall, 2003
18. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
19. Sandler A, Gray R, Perry MC, et al: Paclitxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
20. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
21. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 (Pubitemid 46224178)
22. Van Cutsem E, Vervenne WL, Bennouna J, et al: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231-2237, 2009
23. Kindler HL, Ioka T, Richel DJ, et al: A double-blinded, placebo-controlled, randomised, phase III study of axitinib (AG-013736) plus gemcitabine versus placebo in advanced pancreatic cancer patients. Eur J Cancer Suppl 7:361, 2009 (abstr 6502)
24. Phase 3 trial of aflibercept in metastatic pancreatic cancer discontinued. http://en.sanofi-aventis.com/press/press-releases/2009/ppc-26186. asp
25. Boeck S, Hinke A, Wilkowski R, et al: Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol 13:224-227, 2007 (Pubitemid 46231324)
26. Cannistra SA: Phase II trials in journal of clinical oncology. J Clin Oncol 27:3073-3076, 2009
27. Fukumura D, Jain RK: Tumor microvasculature and micorenvironment: Targets for antiangiogenesis and normalization. Microvasc Res 74: 72-84, 2007
28. Solorzano CC, Baker CH, Bruns CJ, et al: Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase. Cancer Biother Radiopharm 16:359-370, 2001 (Pubitemid 33151113)
29. Bruns CJ, Shrader M, Harbison MT, et al: Effect of the vascular endothelial growth factor receptor-2 antibody DC-101 plus gemcitabine on growth, metastasis, and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 102:101-108, 2002 (Pubitemid 35168021)
30. Korc M: Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2:8, 2003
31. Luo J, Guo P, Matsuda K, et al: Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer 92:361-369, 2001 (Pubitemid 32249712)
32. Bockhorn M, Tsuzuki Y, Xu L, et al: Differential vascular and transcriptional responses to antivascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin Cancer Res 9:4221-4226, 2003 (Pubitemid 37204043)
33. Tsuzuki Y, Mouta Carreira C, Bockhorn M, et al: Pancreas microenvironment promotes VEGF expression and tumor growth: Novel window models for pancreatic tumor angiogensis and microcirculation. Lab Invest 81:1439-1451, 2001 (Pubitemid 32980166)
34. Olive KP, Jacobetz MA, Davidson CJ, et al: Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457-1461, 2009
35. Ebos JM, Lee CR, Kerbel RS: Tumor and host-mediated pathways of resistance and disease progression in response to anti-angiogenic therapy. Clinical Cancer Res 15:5020-5025, 2009
36. Crawford Y, Ferrara N: Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci 30: 624-630, 2009
37. Shaked Y, Henke E, Roodhart JM, et al: Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14:263-273, 2008